Theralase photodynamic compound technology makes strides towards commercialization

Theralase Technologies' (Toronto, ON, Canada) proprietary photodynamic compound (PDC) technology has been approved for use in a live animal bladder cancer model by the University Health Network (UHN; also in Toronto) Research Ethics Board. The approval expedites the company’s progress towards commercializing its advanced bladder cancer therapy.

Theralase's PDC has demonstrated that it is toxic to bladder cancer cells when light-activated, with 100% kill rate. The company will validate its PDC technology in the animal cancer model to support an Investigational New Drug (IND) application to be filed with the FDA later this year. The IND application will allow the company to commence a Phase 1/2a human clinical trial to prove the safety and efficacy of its PDC technology on 30 subjects, with scheduled completion in 2014.

Based on recent pharmaceutical acquisitions for oncology drugs and market statistics, the estimated value of the PDC upon successful completion of the clinical trial ranges from $84 million to $360 million in upfront payments, followed by a double-digit revenue royalty stream, says BIO statistics.


Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Nipro Corporation set to commercialize Infraredx multimodal imaging system in Japan

Nipro Corporation, which is the exclusive distributor of Infraredx's TVC Imaging System, has established a manufacturing subsidiary to produce the system commercially.

LED Medical Diagnostics, BC Cancer Agency, and Genome BC sign agreement to develop oral cancer test

LED Medical Diagnostics has signed an agreement with the BC Cancer Agency and, in turn, Genome British Columbia (Genome BC) to create and commercialize a progression-risk assessment test for oral c...

Michelson Diagnostics closes $3.25 million financing round

Optical coherence tomography (OCT) medical device maker Michelson Diagnostics has closed its Series A2 financing round, raising $3.25 million (£1.98 million) from existing investors.

Carl Zeiss Meditec acquires Aaren Scientific, expanding intraocular lens portfolio

Carl Zeiss Meditec has acquired intraocular (IOL) lens maker Aaren Scientific, thereby expanding its IOL portfolio for ophthalmic surgeons.


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS